For US Residents Only.

Understanding Treatment


Understanding Treatment Understanding Treatment

PROMACTA may increase platelet counts in children 1 year of age and older.

PROMACTA is the first and only approved TPO-receptor agonist for managing pediatric and adult chronic ITP.


PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to chronic immune (idiopathic) thrombocytopenia (ITP) when other medicines to treat your child’s ITP or surgery to remove the spleen have not worked well enough.


PROMACTA is used to try to raise platelet counts in order to lower your child’s risk of bleeding.

PROMACTA is not used to make platelet counts normal.

PROMACTA is for the treatment of certain people with low platelet counts caused by chronic ITP, chronic hepatitis C virus (HCV), or severe aplastic anemia (SAA), not for a precancerous condition called myelodysplastic syndromes (MDS) or low platelet counts caused by other conditions or diseases.

PROMACTA has been approved by the Food and Drug Administration for patients aged 1 year and older with chronic ITP.

PROMACTA is not approved for use in children with SAA or HCV.

How PROMACTA may help your child

If your child has been diagnosed with chronic ITP and other treatments have not worked well enough, the doctor may recommend PROMACTA.


PROMACTA is a once-daily oral medicine that may help to boost your child’s platelet counts and keep them higher than before treatment.